ICH Questions Part 4 Flashcards

1
Q

Double blind study design entails that the following are unaware of the treatment assignment
a) Subject
b) Investigator
c) Monitor
d) All of the above

A

Double blind study design entails that the following are unaware of the treatment assignment
d) All of the above

a) Subject
b) Investigator
c) Monitor

*staff who are involved in the treatment or clinical evaluation of the subjects are not aware of the treatment received. This includes anyone determining subject eligibility, evaluating endpoints or assessing compliance with the protocol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

In a single blind trial the person unaware of the treatment assignment is
a) The subject
b) The investigator
c) The monitor
d) The data analyst

A

In a single blind trial the person unaware of the treatment assignment is
a) The subject

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

The purpose of a double blind design is to ensure
a) Deceive the subject
b) Reduce the bias on the part of the investigator
c) Reduce the bias on the part of the subject
d) Reduce bias on the part of subject and investigator

A

The purpose of a double blind design is to ensure
d) Reduce bias on the part of subject and investigator

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

The types of bias on the part of the investigator that are reduced or eliminated by blinding may include
a) Making Changes in the protocol eligibility criteria that may favor the sponsor
b) Data falsification and fabrication
c) Lack of Reporting of protocol deviations and serious adverse events
d) All of the above

A

The types of bias on the part of the investigator that are reduced or eliminated by blinding may include
d) All of the above

a) Making Changes in the protocol eligibility criteria that may favor the sponsor
b) Data falsification and fabrication
c) Lack of Reporting of protocol deviations and serious adverse events

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

The bias on part of a subject in a clinical trial would best be represented by
a) Complaints to OHRP regarding the IRB
b) Noncompliance with the visitation schedule
c) Altered behavior which may subvert the objective of the trial
d) Non-authorized variation in the drug dosing schedule.

A

The bias on part of a subject in a clinical trial would best be represented by
c) Altered behavior which may subvert the objective of the trial

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

The term CRO stands for
a) Certified research Organization
b) Certified Research Officer
c) Contract Research Official
d) Contract Research Organization

A

The term CRO stands for
d) Contract Research Organization

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Good Clinical Practice represents all of the features below except
a) Is a standard for the design conduct performance of a clinical trial
b) A standard for auditing, recording, monitoring and reporting of a clinical trial
c) Assurance that the data are accurate and credible
e) Assurance that the rights, integrity and confidentiality of trial subjects is protected
f) Represents a mandatory regulatory guidance for clinical trial management

A

Good Clinical Practice represents all of the features below except
f) Represents a mandatory regulatory guidance for clinical trial management

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

A Data and Safety Monitoring Board does all of the following except
a) Supports SAE review by the IRB
b) Assesses progress of a clinical trial and critical efficacy endpoints
c) Monitors all aspects of data safety for a clinical trial
d) Recommends to the sponsor whether a trial should be continued, modified or stopped

A

A Data and Safety Monitoring Board does all of the following except
a) Supports SAE review by the IRB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

An inspection of a clinical trial is all of the following except
a) Usually performed by a regulatory authority
b) Consists of a review of documents, facilities, records and any other resources at the site
c) May occur at the site or at the sponsor or CRO location
d) Is usually integrated into the monitoring schedule.

A

An inspection of a clinical trial is all of the following except
d) Is usually integrated into the monitoring schedule.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

An institution (medical) is defined as a site for clinical trials and includes
a) Any public or private entity or agency
b) A medical facility
c) A dental facility
d) All of the above

A

An institution (medical) is defined as a site for clinical trials and includes
d) All of the above

a) Any public or private entity or agency
b) A medical facility
c) A dental facility

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

An impartial witness is all of the following except
a) A person who cannot be unfairly influenced
b) Attends the informed consent conference when the subject or LAR cannot read
c) Reads any written information supplied to the subject
d) Is usually certified by the institution

A

An impartial witness is all of the following except
d) Is usually certified by the institution

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

A monitor ensures that a clinical trial is being performed as specified in
a) The protocol
b) Standard operating procedures
c) Good Clinical Practice and other regulatory requirements
d) All of the above

A

A monitor ensures that a clinical trial is being performed as specified in
d) all of the above

a) The protocol
b) Standard operating procedures
c) Good Clinical Practice and other regulatory requirements

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

A non clinical study is one which is all of the following except
a) Includes all animal studies
b) Any non human study
c) Usually precedes human studies
d) May apply to human studies with high risk and no benefit

A

A non clinical study is one which is all of the following except
d) May apply to human studies with high risk and no benefit

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Under ICH GCP all of the following apply to a legally authorized representative (LAR) except:
a) Is an individual authorized to consent on behalf of a trial subject
b) Juridical or other body authorized under applicable law to consent on behalf of a trial subject
c) Often consents in situations where the trial subject is unable to consent for himself because of physical or mental limitations
d) Is authorized to make financial decisions on behalf of the trial subject if hospitalized.

A

Under ICH GCP all of the following apply to a legally authorized representative (LAR) except:
d) Is authorized to make financial decisions on behalf of the trial subject if hospitalized.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Under ICH a vulnerable subject may include all of the following except (choose all that apply)
a) Medical pharmacy, dental or nursing students
b) Members of the armed forces
c) Subordinate hospital or laboratory personnel
d) Persons kept in detention
e) Pregnant women
f) Fetuses and neonates
g) Children
h) Unemployed, impoverished or homeless persons
i) Nomads, refugees
j) The elderly
k) Ethnic minority groups
l) Uneducated or illiterate individuals
m) minors
n) people with incurable diseases

A

Under ICH a vulnerable subject may include all of the following except (choose all that apply)
e) Pregnant women
f) Fetuses and neonates
j) The elderly
l) Uneducated or illiterate individuals

*e,f,j are special populations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Central features of a vulnerable subject in ICH GCP include all except
a) Subject influenced by the benefits of participation
b) Subjects influenced by a retaliatory response by a senior member of a hierarchy
c) Subjects of an ethnic minority group
d) Subjects enrolled in more than one clinical trial at the same time

A

Central features of a vulnerable subject in ICH GCP include all except
d) Subjects enrolled in more than one clinical trial at the same time

17
Q

Responsibility for the investigational product rests with the
a Monitor
b) Sponsor
c) CRO
d) Investigator

A

Responsibility for the investigational product rests with the
b) Sponsor

18
Q

Regarding the use of the investigational product the investigator should
a) Maintain records that the subjects were provided with the doses stated in the protocol
b) Ensure that the drug was used only as described in the protocol
c) Should ensure that the drug use is explained to the subject and compliance is verified
d) All of the above

A

Regarding the use of the investigational product the investigator should
d) All of the above

a) Maintain records that the subjects were provided with the doses stated in the protocol
b) Ensure that the drug was used only as described in the protocol
c) Should ensure that the drug use is explained to the subject and compliance is verified

19
Q

If the subject or the LAR is unable to read the informed consent
a) The subject should not be considered for enrollment
b) Written permission should be obtained from the IRB prior to enrollment
c) A family member should be recruited to explain the consent
d) An impartial witness should be present

A

If the subject or the LAR is unable to read the informed consent
d) An impartial witness should be present

20
Q

The primary role of the witness is to ensure that
a) Provide emotional support to the subject
b) Satisfy the IRB that the informed consent process is adequate
c) Ensure that the information was understood and consent freely given by the subject
d) Verify that signatures and dates on the consent are adequate.

A

The primary role of the witness is to ensure that
c) Ensure that the information was understood and consent freely given by the subjec

21
Q

The essential documents for a clinical trial should be retained for
a) At least two years after discontinuation of clinical development of the drug
b) For a period of longer than two years if applicable regulatory requirements demand it
c) As long as the sponsor deems it necessary
d) All of the above

A

The essential documents for a clinical trial should be retained for
d) All of the above

a) At least two years after discontinuation of clinical development of the drug
b) For a period of longer than two years if applicable regulatory requirements demand it
c) As long as the sponsor deems it necessary

22
Q

Premature termination of a clinical trial should be reported by the investigator to
a) The research subjects
b) The regulatory authority if applicable
c) The IRB
d) All of the above

A

Premature termination of a clinical trial should be reported by the investigator to
d) All of the above

a) The research subjects
b) The regulatory authority if applicable
c) The IRB

23
Q

The final report of the investigator should be provided to
a) The IRB
b) The regulatory authority
c) Both a and b
d) The institution

A

The final report of the investigator should be provided to
c) Both a and b

a) The IRB
b) The regulatory authority

24
Q

Individuals utilized by the sponsor for all stages of the clinical trial process may include all of the following except
a) Biostatisticians
b) Clinical pharmacologists
c) Physicians
d) Trial subjects where appropriate

A

Individuals utilized by the sponsor for all stages of the clinical trial process may include all of the following except
d) Trial subjects where appropriate

25
Q

With regard to electronic trial data the sponsor should ensure all of the following except
a) The EDC vendor is approved by the IRB
b) The data changes are documented
c) There is no deletion of entered data
d) An audit, data and edit trials are maintained

A

With regard to electronic trial data the sponsor should ensure all of the following except
a) The EDC vendor is approved by the IRB

26
Q

For identification of all subject data the sponsor should
a) Use the medical record number
b) Use the name
c) Use an identification code
d) Use a social security number or driver’s license number

A

For identification of all subject data the sponsor should
c) Use an identification code

27
Q

Before entering an agreement with the investigator/institution the sponsor should provide
a) The IRB with the protocol
b) The investigator/institution with the protocol only
c) The investigator/institution with investigator’s brochure
d) The investigator/institution with protocol and the investigator’s brochure

A

Before entering an agreement with the investigator/institution the spsnor should provide
d) The investigator/institution with protocol and the investigator’s brochure